세계 줄기세포 분석 시장 규모는 2023년 15억 4,000만 달러에서 2031년 48억 달러에 이를 것으로 예측되며, 2024-2031년 예측 기간에 CAGR로 15.27%의 성장이 예상됩니다. 시장은 최근 몇 년간 현저한 성장을 보이고 있으며 앞으로도 견조한 확대 속도를 유지할 것으로 예상됩니다. 줄기세포 분석은 줄기세포의 특성과 작용을 평가하기 위한 실험방법입니다. 줄기세포의 자기복제능, 다양한 세포종으로의 분화능, 증식능을 평가하기 위해, 관리된 조건하에서 줄기세포를 시험합니다. 줄기 세포 분석은 생물 의학 연구 및 재생 의학에서 중요하며, 약물 및 약물 개발부터 독성 스크리닝 및 질병 모델링에 이르기까지 광범위한 응용이 가능합니다. 또한 줄기세포 분석은 치료제가 될 수 있는 약제가 줄기세포의 분화와 기능성에 미치는 영향을 조사함으로써 의약품 개발에 중요한 역할을 하고 있습니다. 또한 이러한 분석은 발달 과정 연구, 약리학 독성 스크리닝, 암 및 신경 질환과 같은 질병의 근본 원인 규명에도 사용됩니다.
줄기세포 연구의 끊임없는 진보와 줄기세포의 분리·배양·분화를 향한 혁신적인 기술의 등장이 주된 촉진요인이 되고 있습니다. 이러한 기술의 진보는 줄기세포 분석의 효율성과 효능을 높여 창약과 재생의료, 기초연구 등 다양한 용도에서 줄기세포 분석을 점점 매력적으로 하고 있습니다. 3차원 세포 배양법, 고처리량 스크리닝 기법, 이미징 및 분석 기구의 진보 등의 혁신이 총체로서 시장 확대에 기여하고 있습니다.
순환기 질환, 신경 질환, 당뇨병 등 다양한 질병에 대한 줄기 세포의 가능성과 함께 재생 의료에 대한 관심의 급속한 증가가 줄기 세포 분석에 대한 수요를 뒷받침하고 있습니다. 또한, 만성 질환과 유전성 질환의 세계적인 증가로 새로운 치료제와 치료법의 개발이 필요합니다. 줄기세포는 이러한 치료법을 만들어내는 유망한 수단이 되기 때문에 질병 모델링, 의약품 개발, 맞춤형 의료에서 줄기세포 분석에 대한 수요가 촉진되고 있습니다. 학술계와 제약기업이 질병의 병인에 대한 이해를 깊게 하고 새로운 치료법을 평가하는 대처를 강화함에 따라 줄기세포 분석의 필요성은 계속 증가하고 있습니다. 정부, 기업, 학술기관은 치료에 대한 응용을 모색하기 위해 줄기세포 연구에 대한 투자를 늘리고 있으며, 줄기세포를 이용한 치료법의 효능과 안전성을 평가하는 분석에 대한 수요를 창출하고 있습니다. 예를 들어 FUJIFILM Cellular Dynamics는 2022년 3월에 Promega Corporation과 제휴하여 인간 세포 생물학을 궁극적으로 이해하기 위한 시스템에서 세포 생물학이 어떻게 기능하는지를 이해하기 위한 신규 어세이을 개발했습니다.
질병의 유병률 상승
암, 심혈관계 질환, 당뇨병, 신경질환 등의 만성질환과 생활습관병의 유병률 증가는 줄기세포 분석 시장 확대의 중요한 카탈리스트가 되고 있습니다. 돼지 인플루엔자와 에볼라 출혈열과 같은 감염의 급증도 치료제와 의약품 개발 부문의 성장에 박차를 가하고 있습니다. 예를 들어, 2021년 12월 27일-2022년 1월 9일, WHO Global Influenza Surveillance and Response System(GISRS)의 검사실은 99개국의 검사실에서 31만 7,198건 이상의 검체를 분석했습니다. 이들 검사 중 1만 6,862명이 인플루엔자 바이러스 양성으로 판정되었고, 그 63.7%가 A형 인플루엔자, 36.3%가 B형 인플루엔자였습니다. 질병의 유행과 그 반복성은 이러한 질병의 이해와 대책에서 줄기 세포 분석의 중요성을 명시합니다. 또한 노년 인구와 소아 인구가 증가함에 따라 질병의 이환율도 증가하고 줄기 세포 검사에 대한 수요를 더욱 밀어 올리고 있습니다. 2022년 7월 현재 유엔의 예측에 따르면 세계 소아 인구(0-17세)는 23억명으로 2040년에 25억명에 달할 것으로 예측되고 있습니다. 소아 인구의 지속적인 증가는 혁신적인 솔루션에 대한 요구 증가를 의미하며, 줄기 세포 분석 시장은 향후 몇 년동안 지속적인 성장을 보일 것으로 예상됩니다.
이 보고서는 세계 줄기 세포 분석 시장에 대한 조사 분석을 통해 시장 규모와 예측, 시장 역학, 주요 기업 현황과 전망 등의 정보를 제공합니다.
Global stem cell assays market is projected to witness a CAGR of 15.27% during the forecast period 2024-2031, growing from USD 1.54 billion in 2023 to USD 4.8 billion in 2031. The market has experienced significant growth in recent years and is expected to maintain a strong pace of expansion in the coming years. A stem cell assay is a laboratory method used to evaluate the characteristics and actions of stem cells. It involves testing stem cells under controlled conditions to assess their capacity for self-renewal, differentiation into various cell types, and proliferation. Stem cell assays are important in biomedical research and regenerative medicine, offering applications ranging from drug discovery and development to toxicological screening and disease modeling. Moreover, stem cell assays play a crucial role in drug development by examining the effects of potential therapeutic drugs on stem cell differentiation and functionality. Additionally, these assays are employed to study developmental processes, screen for pharmacological toxicities, and investigate the underlying causes of diseases such as cancer and neurological disorders.
Constant progress in stem cell research, coupled with the emergence of innovative techniques for stem cell isolation, cultivation, and differentiation, serve as primary drivers. These technological advancements enhance the efficiency and efficacy of stem cell assays, rendering them increasingly attractive for various applications, including drug development, regenerative medicine, and fundamental research. Innovations such as 3D cell culture methodologies, high-throughput screening approaches, and advancements in imaging and analytical instruments collectively contribute to market expansion.
The burgeoning interest in regenerative medicine, alongside the potential of stem cells to address various ailments such as cardiovascular disease, neurological disorders, and diabetes, fuels the demand for stem cell assays. Moreover, the rising global prevalence of chronic diseases and genetic disorders necessitates the development of novel therapeutics and treatments. Stem cells offer a promising avenue for generating such therapies, consequently driving the demand for stem cell assays in disease modeling, drug development, and personalized medicine. As academia and pharmaceutical companies intensify efforts to deepen their understanding of disease etiology and evaluate new treatments, the necessity for stem cell assays continues to grow. Governments, corporations, and academic institutions are increasingly investing in stem cell research to explore therapeutic applications, thereby generating demand for assays to assess stem cell-based therapies' efficacy and safety. For instance, Fujifilm cellular dynamics collaborated with Promega Corporation in March 2022 to develop novel assays to understand how cellular biology works in a system to understand cell biology in humans ultimately.
Rising Prevalence of Diseases
The increasing prevalence of chronic diseases and lifestyle-related disorders, including cancer, cardiovascular conditions, diabetes, and neurological ailments, serves as a significant catalyst for the expansion of the stem cell assay market. The upsurge in infectious diseases, such as swine flu and Ebola, has also fueled growth in the therapeutics and drug development sector. For instance, between December 27, 2021, and January 9, 2022, WHO Global Influenza Surveillance and Response System (GISRS) laboratories analyzed over 317,198 specimens from labs across 99 countries. Among these tests, 16,862 individuals tested positive for influenza viruses, with 63.7% identified as influenza A and 36.3% as influenza B. The prevalence of diseases and their recurring nature underscore the importance of stem cell assays in understanding and combating these conditions. Moreover, the expanding geriatric and pediatric populations drive the increased incidence of diseases, further boosting the demand for stem cell assays. As of July 2022, United Nations Projections indicated a global pediatric population (0-17 years) of 2.3 billion, projected to reach 2.5 billion by 2040. The ongoing rise in the pediatric population signifies a growing need for innovative solutions, positioning the stem cell assays market for sustained growth in the coming years.
Growing Emphasis On Clinical Research & Development
The expansion of the global stem cell assays market is being propelled by factors such as clinical research and development. There is a strong emphasis on comprehending cancer biology and identifying innovative therapeutic targets for a wide range of acute and chronic diseases, significantly contributing to the growth of the stem cell assays market. Moreover, substantial investments in research and development endeavors by pharmaceutical companies and academic institutions are fostering market expansion. The escalating prevalence of chronic diseases such as cancer, osteoarthritis, cardiovascular diseases, and diabetes drives the demand for cell-based assays in the quest for novel drug discoveries, thereby serving as a pivotal growth factor for this market segment. According to an article titled "2022 Funding forecast: strong R&D growth with clouds on the horizon," published in April 2022, the United States federal government is projected to allocate USD 181.4 billion for research and development in 2022, further bolstering growth prospects for this segment.
Clinical trials play a pivotal role in assessing the safety and efficacy of new drugs, ultimately leading to regulatory approvals and market penetration. These trials validate the therapeutic potential of drugs and augment the empirical evidence supporting their clinical utility. Additionally, collaboration among commercial entities, academic institutions, and regulatory bodies expedites the clinical development process of various stem cell assays and accelerates the introduction of novel drugs to the market. In April 2023, Omisirge (omidubicel-onlv), a significantly modified allogeneic (donor) cord blood-based cell therapy was granted approval by US FDA.
Dominance of Reagent and Kits
During the projected period, the reagents and kits segment are expected to lead the stem cell assays market. These consumables play a vital role in various stem cell tests, encompassing cell proliferation, differentiation, viability, and toxicity assessments. Their pervasive use in routine laboratory operations and recurring necessity contribute to their high demand. This demand is fueled by ongoing research and development endeavors in both academic and commercial sectors, where stem cell assays are pivotal for drug discovery, therapeutic advancement, and fundamental research. Reagents and kits are formulated to address a broad spectrum of requirements, ranging from fundamental research to specialized therapeutic domains. This adaptability is reinforced by the capacity to customize kits for specific stem cell types or assays. Such tailored solutions and application versatility ensure sustained high demand for reagents and kits across diverse research domains and pharmaceutical development initiatives, consolidating their market dominance. Moreover, in contrast to instruments, which entail significant upfront capital investment and maintenance costs, reagents and kits are more cost-effective and accessible to a broader customer base, including small research laboratories and entrepreneurs. In March 2022, Illumina launched the TruSight Oncology (TSO) comprehensive in-vitro genomic profiling kit in Europe. The kit evaluates multiple genes and biomarkers to elucidate the precise molecular profile of cancer patients, empowering clinicians to administer tailored therapies based on individual molecular profiles.
North America Dominates Global Stem Cell Assays Market Share
North America dominates the global stem cell assays market, primarily due to its well-established healthcare sector and widespread adoption of cell-based assays. In the United States, the rising incidence of chronic diseases like cancer, osteoarthritis, and diabetes drives demand for cell-based assays, thus serving as a significant growth driver for this market.
For instance, according to data from the American Cancer Society's Cancer Facts & Figures 2022 report, an estimated 1.9 million new cancer cases will be diagnosed in the United States, along with 609,360 cancer-related deaths. Similarly, American Heart Association reported in January 2022 that a myocardial infarction occurs approximately every 40 seconds in the United States. Such high prevalence of chronic diseases in the population of the United States is expected to propel stem cell assays market growth during the forecast period.
Future Market Scenario (2024 - 2031F)
Occurrence and re-occurrence in number of acute and non-acute diseases call for a solution and it presents the biggest opportunity for the stem cell assays market to rise. Adoption of much advanced and effective approaches are being devised that should ensure faster recovery and better results for a better quality of life. R&D and heavy investments made by healthcare giants are promoting developments in the stem cell assays market, which is optimistic for the market to flourish in the coming years. New brands in this development area are introducing themselves with cutting edge technologies.
For instance, in February 2024, Thermo Fisher unveiled a novel serum-free stem cell culture medium designed to enhance stem cell proliferation and differentiation. The breakthrough holds significant promise for companies engaged in developing stem cell-based therapies. Successful attempts to improve diagnostics push the industry as a whole to engage further with higher-quality R&D, which paves the way for the market to rise. In August 2022, Life Net Health LifeSciences launched Cell-Based Assay Services, including cytotoxicity screening, biocompatibility assays, and others.
Key Players Landscape and Outlook
Several companies in global stem cell assays market are focusing on new product release, market expansion, and product development. Stem cell assays market players are poised to encounter promising growth prospects in the global market, driven by the increasing demand for diagnostic solutions. The primary focus of these leading players is directed towards the rapidly expanding market segment, aiming to thrive and excel in an intensely competitive market environment. Additionally, these market players emphasize collaboration and license agreements as strategic initiatives are anticipated to propel the market growth.
In July 2022, CORESTEM, based in South Korea, continued to enroll participants for the Phase 3 clinical trial of NeuroNata-R. The treatment has obtained conditional approval for the treatment of amyotrophic lateral sclerosis (ALS) patients in South Korea.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.